Sun Pharma starts succession plan; Ganorkar succeeds Shanghvi as MD

Dilip Shanghvi to remain executive chairman while Ganorkar takes charge as MD from September 1 and Aalok Shanghvi is given additional charge of North America business

Sixty-nine-year-old Dilip Shanghvi is handing over the baton to his long-term colleague Kirti Ganorkar as the managing director (MD) of Sun Pharmaceutical Industries, a ₹52,041 crore global pharma firm. The company said the move is part of “structured and forward-looking succession planning”.

 

Dilip’s son Aalok Shanghvi, who serves as whole-time director and chief operating officer (COO), has been given additional responsibility of the North America business as Abhay Gandhi, current president and chief executive officer (CEO) of Sun’s North America business, moves on. Gandhi has, in fact, decided to pursue his interests outside Sun.

 

Industry watchers say that experience in